 |
Treating Non-muscle-invasive Bladder Cancer: The AUA 2007 Update CME Author Information and Disclosures Release Date: January 10, 2008; Valid for credit through January 10, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Treating Non-muscle-invasive Bladder Cancer: The AUA 2007 UpdateSam S. Chang, MDM. Craig Hall, MDGuido Dalbagni, MD, FACSRaj Som Pruthi, MDPaul F. Schellhammer, MDJohn Derek Seigne, MDEila C. Skinner, MDJ. Stuart Wolf, MD
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe the methodology used in preparing the AUA guideline on the treatment of non-muscle-invasive bladder cancer, including the criteria for the 3 levels of guideline statement -- standard, recommendation, and option
- Review the principal
treatment options in relation to risk for recurrence
- Describe the guideline statements for treatment on the basis of 5 patient profiles, or "index patient" groups
Author Disclosures Sam S. Chang, MD
Disclosure: Sam S. Chang, MD, has disclosed that he has served as an advisor or consultant for Indevus,
sanofi-aventis, and TetraLogic. M. Craig Hall, MD
Disclosure: M. Craig Hall, MD, has disclosed no relevant financial relationships. Guido Dalbagni, MD, FACS
Disclosure: Guido Dalbagni, MD, FACS, has disclosed no relevant financial relationships. Raj Som Pruthi, MD
Disclosure: Raj Som Pruthi,
MD, has disclosed no relevant financial relationships. Paul F. Schellhammer, MD
Disclosure: Paul F. Schellhammer, MD, has disclosed no relevant financial relationships. John Derek Seigne, MD
Disclosure: John Derek Seigne, MD, has disclosed that he owns stock, stock options, or bonds in Pfizer, Johnson & Johnson, and Bristol-Myers Squibb. Dr. Seigne has
also disclosed that he has received grants for clinical research from the Foundation for Informed Medical Decision Making. Eila C. Skinner, MD
Disclosure: Eila C. Skinner, MD, has disclosed no relevant financial relationships. J. Stuart Wolf, Jr., MD
Disclosure: J. Stuart Wolf, Jr., MD, has disclosed that he has served as an advisor or consultant to Omerus
and Terumo Corporation. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
